Richard Wilson is currently the Senior Vice President, Primary Focus Lead of Genetic Regulation at Astellas Gene Therapies and is responsible for setting and leading the gene therapy strategy for Astellas’ Primary Focus Genetic Regulation. Richard joined Astellas Gene Therapies (formerly Audentes Therapeutics) in April 2020 as Vice President, Program Management. Richard has over 30 years of experience in research, development, and commercialization of small molecules, biological and gene therapies. Prior to Astellas Gene Therapies, he served as Executive Director, Product Portfolio Development at BioMarin Pharmaceutical Inc. where he held a number of roles including portfolio Core Team leader for BioMarin’s PKU franchise, overseeing the approval and global launch of the first enzyme substitution therapy for PKU. Prior to BioMarin, Richard held leadership positions in GlaxoWellcome, BioChem Pharma, Theravance and Innoviva, where he was involved in the development and commercialization of a range of products in COPD and Asthma, and led R&D programs in anti-infective, cardiovascular, rheumatology, and urology disease areas. Richard holds a BSc (Hons) in Chemistry from the University of Manchester and an MBA from the Haas School of Business at the University of California, Berkeley.